Cybin (TSE:CYBN) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Cybin Inc. is set to present promising 12-month data from its Phase 2 study of CYB003, aimed at treating Major Depressive Disorder, in an upcoming webcast. The company is also moving forward with its Phase 3 PARADIGM program, highlighting its commitment to revolutionizing mental healthcare. Investors and stakeholders are invited to join the discussion for insights into these innovative treatment developments.
For further insights into TSE:CYBN stock, check out TipRanks’ Stock Analysis page.
